Sandbox Reserved 383: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 21: | Line 21: | ||
*Eticlopride | *Eticlopride | ||
*Nafadotride | *Nafadotride | ||
Two ligands that are associated with dopamine D3 receptor are 3-chloro-5-ethyl-N{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-6-hydroxyl-2-methyloxybenzamide (<scene name='Sandbox_Reserved_383/Etq/1'>ETQ</scene>) and maltose (<scene name='Sandbox_Reserved_383/Mal/1'>MAL</scene>). ETQ binds to dopamine D3 receptor by Asp 110A and Phe346A. MAL binds by Asp 1020A, Glu 1022A, Glu1011A, and Leu1032A.< | Two ligands that are associated with dopamine D3 receptor are 3-chloro-5-ethyl-N{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-6-hydroxyl-2-methyloxybenzamide (<scene name='Sandbox_Reserved_383/Etq/1'>ETQ</scene>) and maltose (<scene name='Sandbox_Reserved_383/Mal/1'>MAL</scene>). ETQ binds to dopamine D3 receptor by Asp 110A and Phe346A. MAL binds by Asp 1020A, Glu 1022A, Glu1011A, and Leu1032A.<http://www.pdb.org/pdb/explore.do?structureId=3PBL/> | ||
==Diseases== | ==Diseases== | ||
Variations in the DRD3 gene is connected with essential tremor hereditary type 1 (ETM1). ETM1 is the most common movement disorder involving postural tremor of the arms, head, legs, body core, voice, jaw, and other facial muscles. This condition can be provoked by emotions, hunger, fatigue, and temperature extremes.<ref>"Linkage with the Ser9Gly DRD3 polymorphism in essential tremor families." | Variations in the DRD3 gene is connected with essential tremor hereditary type 1 (ETM1). ETM1 is the most common movement disorder involving postural tremor of the arms, head, legs, body core, voice, jaw, and other facial muscles. This condition can be provoked by emotions, hunger, fatigue, and temperature extremes.<ref>"Linkage with the Ser9Gly DRD3 polymorphism in essential tremor families." | ||
| Line 27: | Line 27: | ||
Clin. Genet. 69:437-440(2006) [PubMed: 16650084] [Abstract]</ref><ref>"A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor." | Clin. Genet. 69:437-440(2006) [PubMed: 16650084] [Abstract]</ref><ref>"A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor." | ||
Jeanneteau F., Funalot B., Jankovic J., Deng H., Lagarde J.-P., Lucotte G., Sokoloff P. | Jeanneteau F., Funalot B., Jankovic J., Deng H., Lagarde J.-P., Lucotte G., Sokoloff P. | ||
Proc. Natl. Acad. Sci. U.S.A. 103:10753-10758(2006) [PubMed: 16809426] [Abstract]</ref> Disorders that are linked to variations in the DRD3 gene include social phobia<ref>Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M (2000). "Low dopamine D(2) receptor binding potential in social phobia". Am J Psychiatry 157 (3): 457–459. doi:10.1176/appi.ajp.157.3.457. PMID 10698826.</ref>, Tourette’s syndrome<ref>11Kienast T, Heinz A (2006). "Dopamine and the diseased brain". CNS Neurol Disord Drug Targets 5 (1): 109–31. doi:10.2174/187152706784111560. PMID 16613557.</ref>, Parkinson’s disease<ref>Fuxe K, Manger P, Genedani S, Agnati L (2006). The nigrostriatal DA pathway and Parkinson’s disease. "The nigrostriatal DA pathway and Parkinson's disease". J Neural Transm Suppl. Journal of Neural Transmission. Supplementa 70 (70): 71–83. doi:10.1007/978-3-211-45295-0_13. ISBN 978-3-211-28927-3. PMID 17017512.</ref>, schizophrenia< | Proc. Natl. Acad. Sci. U.S.A. 103:10753-10758(2006) [PubMed: 16809426] [Abstract]</ref> Disorders that are linked to variations in the DRD3 gene include social phobia<ref>Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M (2000). "Low dopamine D(2) receptor binding potential in social phobia". Am J Psychiatry 157 (3): 457–459. doi:10.1176/appi.ajp.157.3.457. PMID 10698826.</ref>, Tourette’s syndrome<ref>11Kienast T, Heinz A (2006). "Dopamine and the diseased brain". CNS Neurol Disord Drug Targets 5 (1): 109–31. doi:10.2174/187152706784111560. PMID 16613557.</ref>, Parkinson’s disease<ref>Fuxe K, Manger P, Genedani S, Agnati L (2006). The nigrostriatal DA pathway and Parkinson’s disease. "The nigrostriatal DA pathway and Parkinson's disease". J Neural Transm Suppl. Journal of Neural Transmission. Supplementa 70 (70): 71–83. doi:10.1007/978-3-211-45295-0_13. ISBN 978-3-211-28927-3. PMID 17017512.</ref>, schizophrenia<Kienast T, Heinz A (2006). "Dopamine and the diseased brain". CNS Neurol Disord Drug Targets 5 (1): 109–31. doi:10.2174/187152706784111560. PMID 16613557./>, neuroleptic malignant syndrome<ref>13Mihara K, Kondo T, Suzuki A, et al. (2003). "Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome". Am. J. Med. Genet. B Neuropsychiatr. Genet. 117 (1): 57–60. doi:10.1002/ajmg.b.10025. PMID 12555236.</ref>, attention-deficit hyperactivinty disorder (ADHD)<ref>Faraone S, Khan S (2006). "Candidate gene studies of attention-deficit/hyperactivity disorder". J Clin Psychiatry 67 Suppl 8: 13–20. PMID 16961425.</ref>, and drug and alcohol dependence<Kienast T, Heinz A (2006). "Dopamine and the diseased brain". CNS Neurol Disord Drug Targets 5 (1): 109–31. doi:10.2174/187152706784111560. PMID 16613557./> <ref>Hummel M, Unterwald E (2002). "D1 dopamine receptor: a putative neurochemical and behavioral link to cocaine action". J Cell Physiol 191 (1): 17–27. doi:10.1002/jcp.10078. PMID 11920678</ref>. | ||
==References== | ==References== | ||
#<Girault J, Greengard P (2004). "The neurobiology of dopamine signaling". Arch Neurol 61 (5): 641–4. doi:10.1001/archneur.61.5.641. PMID 15148138./> | #<Girault J, Greengard P (2004). "The neurobiology of dopamine signaling". Arch Neurol 61 (5): 641–4. doi:10.1001/archneur.61.5.641. PMID 15148138./> | ||
